KS @Calvsams

New York, USA Joined June 2015

Tweets

712
Followers

316
Following

2K
Likes

5K

KS @Calvsams

2 weeks ago

Any thoughts on Treeline's pan-kras? We expect ‘372 to differentiate in the clinic based on its ability to achieve therapeutic free-drug exposures throughout the dosing period and to avoid HRAS and NRAS mediated toxicities. This profile should allow for the deep target inhibition required for single-agent responses, as well as for dose intense combinability with cytotoxics, immunotherapies, anti-EGFR antibodies and other drug classes. We believe strongly—because of the biology of RAS mutated cancers—that dose intense combination regimens are the future of the field, especially in earlier lines of therapy. We are enrolling a Phase 1 dose escalation trial for TLN-372 in patients with KRAS mutant or KRAS wild-type amplified solid tumors. Currently in our fourth dose level, we are solidly on thesis, with PK observed to date in patients consistent with preclinical modeling. We believe ‘372 has the potential to avoid the drug exposure limitations that have been common in the KRAS inhibitor field. We are optimistic that we will be able to reach our pharmacokinetic objectives and that selectivity against HRAS and NRAS will avoid some of the toxicities that have limited dose intensity for other programs.

0 0 0 25 0

View Details

KS @Calvsams

3 weeks ago

@financebully Any thoughts on Treeline's pan-kras?

1 0 1 78 0

View Details

KS @Calvsams

3 weeks ago

@adamfeuerstein Adam, what do you think the reception for this will be?

0 0 0 139 0

View Details

KS @Calvsams

3 weeks ago

$csu disclosed a small stake in UK listed Accesso $acso, easy to miss if you don't own it.

3 0 2 755 1

View Details

KS @Calvsams

4 weeks ago

@ZeeContrarian1 Why terrible management?

0 0 0 79 0

View Details

KS @Calvsams

4 weeks ago

@Process_Cap @curbyourfomo1 @HotshotWake Just hit youtube if you're still looking for the pitch.

2 0 0 59 0

View Details

KS @Calvsams

a month ago

@NestBetter More of a '28 story now. A lost customer and headwinds in HA revenue + lack of launches pushed things out a year.

1 0 2 75 0

View Details

KS @Calvsams

a month ago

@evrgn11112231 @WaterworldCapi1 @CapArtichoke @Process_Cap @OnodaCapital Agree. Flywheel is in motion, very good execution.

0 0 1 72 0

View Details

KS @Calvsams

2 months ago

@patienceisking @haloaerospace I thought their earnings were pretty strong. Think it was bid up on the increased wildfire activity YTD, but as they have demonstrated, their earnings are increasingly uncorrelated with acres burned.

1 0 1 69 0

View Details

KS @Calvsams

2 months ago

@Sher_East_ Ever since they suspended calls their earnings have been a snoozefest. The only notable event this Q is the Somalogic cash hits their books, so it will finally screen as cash rich vs proforma.

0 0 1 39 1

View Details

KS @Calvsams

2 years ago

Any $lab owners out there? Standard Biotools, f/k/a Fluidigm, was recapped by Viking and Casdin in April ’22 after a failed sales process. Viking/Casdin backed a private vehicle led by Dr. Michael Egholm (former CTO of Danaher LS) to build a platform for high-impact, sub-scale tools. Their first deal was injecting $250m to reset the business and pursue M&A. 1/

1 0 3 1K 5

View Details

KS @Calvsams

2 months ago

@xiangtaner Couldn't really speculate. They can go in a lot of directions from here. They disclosed a small stake in a VC backed co last Q, otherwise very little info on targets.

1 0 1 58 0

View Details

KS @Calvsams

2 months ago

@unciacapital @rsandler21969 I cold emailed @rsandler21969 as a badger alum ~15 years ago to get advice on how to break into investing. He was one of the few alums who called me and was super generous and helpful. Thanks Ricky, great run.

1 0 33 2K 2

View Details

KS @Calvsams

2 months ago

@andrewpannu Sleuth

1 0 1 32 0

View Details

KS @Calvsams

2 months ago

@ElliotTurn @twiii_podcast @mihaljevic Thanks Elliot!

0 0 0 32 0

View Details

KS @Calvsams

3 months ago

This is my last friendly reminder that you can buy $1.40-1.50 in cash per share for 88 cents, with a business thrown in for free. $lab

2 0 2 334 3

View Details

KS @Calvsams

4 months ago

Hard to lose money *permanently* - we're down to 98 cents, 30-35% discount to cash per share inclusive of 2026 burn. Exiting '26 at breakeven on flat revs and already operationalized cost outs. The key factor is what do they buy and could they destroy so much value via M&A that the margin of safety erodes? I think unlikely given the depth of their pipeline, years of cultivation, the multi-year slog in LS tools putting pressure on balance sheets and bringing in bid/asks. More likely they buy cash burning tools that take time to work to breakeven, and valuation remains depressed through the digestion period. This sideways case is my downside case, I can't imagine capital impairment from these levels. I think their experience with Somalogic will push them towards underwriting where the cost outs / lean outs do the heavy lifting. $lab

1 0 1 302 0

View Details

KS @Calvsams

3 months ago

@6d617474 @GreenhavenRoad Appreciate these good thoughts.

0 0 1 114 0

View Details

KS @Calvsams

3 months ago

@ericripert @randomhouse @nigelparryphoto Excited for this one!!

0 0 1 48 0

View Details

KS @Calvsams

3 months ago

@6d617474 @GreenhavenRoad My point is there's a skew because those assumptions are unrealistically pessimistic.

1 0 0 120 0

View Details

KS @Calvsams

3 months ago

I agree with your take. I think the most interesting part of this set-up is that you can kitchen sink their guide and still get to $7-8 per share in 2029. Assumptions: -HA revs decline $20m and stay flat -Dev rev small step up, then flat -Base FF ~inflation like growth -7m lost customer -Alcon contracted step-up is pushed out and feathered in through '30 -ZERO Phase III trials converting -ZERO new business Gets me to ~$160m in revs / $36m in EBITDA in 2029. Implies only 35-40% utilization and thus a higher multiple would be appropriate to compensate for the under utilized lines. But even 15-17x multiple gets you to $7-8/share. + a call option on execution to their base case.